Category: <span>immunotherapy clinical trial</span>

Category: immunotherapy clinical trial

immunotherapy clinical trial, immunotherapy for cancer, mesothelioma, mesothelioma clinical trials, mesothelioma immunotherapy, Mesothelioma News, ONCOS 102

ONCOS-102 Mesothelioma Clinical Trial Promises Hope

 

Scandinavian-based Targovax launched the latest immunotherapy clinical trial for pleural mesothelioma, hoping it delivers a better way to treat patients with asbestos-related diseases. The randomized phase Ib/II trial evaluates the performance of ONCOS-102, an engineered human adenovirus designed to induce systemic, anti-tumor responses. Researchers are administering the immunotherapy drug as first-line therapy in combination with…

The post ONCOS-102 Mesothelioma Clinical Trial Promises Hope appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

immunotherapy clinical trial, immunotherapy for cancer, mesothelioma, mesothelioma clinical trials, mesothelioma immunotherapy, Mesothelioma News, ONCOS 102

ONCOS-102 Mesothelioma Clinical Trial Promises Hope

 

Scandinavian-based Targovax launched the latest immunotherapy clinical trial for pleural mesothelioma, hoping it delivers a better way to treat patients with asbestos-related diseases. The randomized phase Ib/II trial evaluates the performance of ONCOS-102, an engineered human adenovirus designed to induce systemic, anti-tumor responses. Researchers are administering the immunotherapy drug as first-line therapy in combination with…

The post ONCOS-102 Mesothelioma Clinical Trial Promises Hope appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

immunotherapy clinical trial, immunotherapy for cancer, mesothelioma, mesothelioma clinical trials, mesothelioma immunotherapy, Mesothelioma News, ONCOS 102

ONCOS-102 Mesothelioma Clinical Trial Promises Hope

 

Scandinavian-based Targovax launched the latest immunotherapy clinical trial for pleural mesothelioma, hoping it delivers a better way to treat patients with asbestos-related diseases. The randomized phase Ib/II trial evaluates the performance of ONCOS-102, an engineered human adenovirus designed to induce systemic, anti-tumor responses. Researchers are administering the immunotherapy drug as first-line therapy in combination with…

The post ONCOS-102 Mesothelioma Clinical Trial Promises Hope appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

clinical trial, Immunotherapy, immunotherapy clinical trial, immunotherapy for mesothelioma, Mesothelioma News, Mesothelioma Research, Mesothelioma treatment, raffitt hassan

Immunotherapy Trial for Mesothelioma Shows Early Promise

 

The immunotherapy drug avelumab showed promising results in a recent phase I clinical trial for malignant mesothelioma, raising hopes as a future second-line therapy. The clinical trial included 53 patients with pleural or peritoneal mesothelioma. It was part of the JAVELIN development program for avelumab, a series of clinical studies testing the drug on about…

The post Immunotherapy Trial for Mesothelioma Shows Early Promise appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.